Novartis’ heart failure med Entresto scores an expanded approval in the US
Extended indication in chronic heart failure authorised by the FDA
Read More
Tag: Entresto
Novartis announces positive results from two Entresto trials
Heart failure is a chronic and progressive condition, which impacts 26 million people worldwide.
Read More
Timely use of Novartis’ Entresto could save thousands of lives
Timely and broad adoption of Novartis’ Entresto by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the US alone, finds a new analysis published in JAMA Cardiology.
Read More
Global guidelines back Novartis’ heart drug Entresto
Novartis’ ‘breakthrough’ therapy Entresto has received a strong endorsement in updated EU and US guidelines on the treatment of heart failure.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
